Fargelin Hemorrhoidal

Calamine, Petrolatum And Phenylephrine Hydrochloride


Madison One Acme Inc
Human Otc Drug
NDC 55614-610
Fargelin Hemorrhoidal also known as Calamine, Petrolatum And Phenylephrine Hydrochloride is a human otc drug labeled by 'Madison One Acme Inc'. National Drug Code (NDC) number for Fargelin Hemorrhoidal is 55614-610. This drug is available in dosage form of Ointment. The names of the active, medicinal ingredients in Fargelin Hemorrhoidal drug includes Ferric Oxide Red - .05 g/100g Petrolatum - 79.25 g/100g Phenylephrine Hydrochloride - .25 g/100g Zinc Oxide - 10.3 g/100g . The currest status of Fargelin Hemorrhoidal drug is Active.

Drug Information:

Drug NDC: 55614-610
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Fargelin Hemorrhoidal
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Calamine, Petrolatum And Phenylephrine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Madison One Acme Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Ointment
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:FERRIC OXIDE RED - .05 g/100g
PETROLATUM - 79.25 g/100g
PHENYLEPHRINE HYDROCHLORIDE - .25 g/100g
ZINC OXIDE - 10.3 g/100g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:RECTAL
TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 27 Nov, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 05 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part346
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:MADISON ONE ACME INC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:1K09F3G675
4T6H12BN9U
04JA59TNSJ
SOI2LOH54Z
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Adrenergic alpha1-Agonists [MoA]
alpha-1 Adrenergic Agonist [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
55614-610-0120 g in 1 TUBE, WITH APPLICATOR (55614-610-01)27 Nov, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose hemorrhoidal (anorectal) astringent/protectant hemorrhoidal (anorectal) protectant hemorrhoidal (anorectal) vasoconstrictor

Product Elements:

Fargelin hemorrhoidal calamine, petrolatum and phenylephrine hydrochloride zinc oxide zinc oxide ferric oxide red ferric oxide red petrolatum petrolatum phenylephrine hydrochloride phenylephrine amber callicarpa nudiflora leaf corydalis yanhusuo tuber lanolin panax notoginseng root pearl (hyriopsis cumingii) sanguisorba officinalis root scutellaria baicalensis root sodium borate styphnolobium japonicum flower

Indications and Usage:

Uses temporarily helps relieve: anorectal burning, itching, and discomfort associated with hemorrhoids temporarily: reduces the swelling associated with irritated hemorrhoidal tissue and other anorectal disorders shrinks hemorrhoidal tissue protects inflamed perianal skin and irritated areas

Warnings:

Warnings for rectal use only

When Using:

When using this product in case of bleeding; consult a doctor promptly do not exceed the recommended daily dosage unless directed by a doctor do not use with an applicator if the introduction of the applicator into the rectum causes additional pain. consult a doctor promptly.

Dosage and Administration:

Directions adults: when practical, cleanse the affected area with mild soap and warm water and rinse thoroughly. gently dry by patting or blotting with toilet tissue or a soft cloth before application of this product. for external hemorrhoids, apply a small amount of ointment directly to the affected area up to 4 times daily. for intrarectal use (internal hemorrhoids): attach applicator to tube. lubricate applicator well, then gently insert applicator into the rectum. squeeze a small amount (2 g) of the ointment into the rectum. remove and discard used applicator. apply to the affected area up to 4 times daily. children under 12 years of age: consult a doctor.

Stop Use:

Stop use and ask a doctor if condition worsens symptoms do not improve within 7 days

Package Label Principal Display Panel:

Fargelin hemorrhoidal ointment ndc 55614-610-01 0.705 oz (20 g) box-02.jpg

Further Questions:

Questions or comments? (888) 221-3496 m-f 9 am to 5 pm


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.